Financial Performance - Revenue for Q3 2021 reached ¥258,468,655.81, an increase of 11.37% year-over-year, and total revenue for the year-to-date was ¥882,076,420.50, up 21.66% compared to the same period last year[3] - Net profit attributable to shareholders for Q3 2021 was ¥12,578,394.22, representing a significant increase of 204.17% year-over-year, with year-to-date net profit at ¥31,582,000.79, up 164.29%[3] - The basic earnings per share for Q3 2021 was ¥0.1178, an increase of 204.34% year-over-year, while the diluted earnings per share also stood at ¥0.1178, up 205.56%[3] - Total operating revenue for Q3 2021 reached CNY 882,076,420.50, an increase of 21.7% compared to CNY 725,008,466.40 in the same period last year[21] - Net profit for Q3 2021 was CNY 30,207,464.49, a significant recovery from a net loss of CNY 59,283,354.55 in the previous year[22] - Earnings per share for Q3 2021 were CNY 0.2978, compared to a loss per share of CNY 0.4595 in the same quarter last year[23] - The company reported a total comprehensive income of CNY 32,562,901.09 for Q3 2021, recovering from a loss of CNY 59,283,354.55 in the previous year[23] Assets and Liabilities - Total assets as of the end of Q3 2021 were ¥3,048,613,279.71, reflecting a growth of 7.30% from the end of the previous year[3] - The company's total assets increased to CNY 3,048,613,279.71, up from CNY 2,841,295,244.66 year-over-year[19] - Total liabilities rose to CNY 1,324,660,962.86, compared to CNY 1,149,916,239.64 in the previous year, indicating a year-over-year increase of 15.2%[19] - The company's equity attributable to shareholders increased to CNY 1,676,693,530.56, up from CNY 1,643,008,784.70[19] - The company’s total equity attributable to shareholders was ¥1,676,693,530.56, a slight increase of 2.05% from the end of the previous year[3] Cash Flow - The company reported a net cash flow from operating activities of ¥34,619,403.71 year-to-date, which is a decrease of 86.45% compared to the same period last year[3] - The net cash flow from operating activities was 34,619,403.71, a decrease of 86.4% compared to 255,467,635.44 in the previous period[26] - Cash inflow from operating activities totaled 650,380,676.22, down 6.9% from 698,176,828.78 in the previous period[26] - Cash outflow from operating activities increased to 615,761,272.51, up 39.0% from 442,709,193.34 in the previous period[26] - The net cash flow from investing activities was -270,485,660.90, worsening from -123,559,294.95 in the previous period[26] - Cash inflow from financing activities was 468,772,392.51, an increase of 15.7% compared to 405,000,000.00 in the previous period[26] - The net cash flow from financing activities improved to 52,683,921.28, compared to -134,660,452.16 in the previous period[26] - The total cash and cash equivalents at the end of the period was 60,765,676.58, down from 157,087,291.42 in the previous period[26] Shareholder Information - Total number of common shareholders at the end of the reporting period is 12,062[11] - The largest shareholder, Shandong Runxin Investment Co., Ltd., holds 37.11% of shares, totaling 39,802,720 shares[11] - The second-largest shareholder, Mi Chaojie, holds 22.79% of shares, totaling 24,448,000 shares[11] Research and Development - Research and development expenses for the year-to-date increased to ¥3,414.07 million, a rise of 36.26% compared to the same period last year, driven by increased project activity[9] - Research and development expenses for Q3 2021 were CNY 34,140,716.76, compared to CNY 25,054,992.89 in the same period last year, marking a 36.3% increase[22] Tax and Other Liabilities - The company reported a significant increase in tax liabilities, with amounts due rising by 241.02% year-over-year to ¥1,064.59 million, reflecting increased business activity[9] - The company received 4,194,489.51 in tax refunds, significantly up from 994,103.21 in the previous period[26] Inventory and Receivables - The company’s accounts receivable increased by 96.40% year-over-year to ¥19,803.34 million, attributed to higher business volume[8] - Accounts receivable increased to ¥198,033,437.81 from ¥100,833,276.47 year-over-year[17] - Inventory as of September 30, 2021, is ¥533,188,364.38, slightly up from ¥532,404,151.77 at the end of 2020[17] Company Plans and Approvals - The company plans to issue A-shares to specific investors, pending approval from the Shenzhen Stock Exchange and the China Securities Regulatory Commission[13] - The company is actively engaging with intermediaries to address inquiries related to the A-share issuance process[14] Reporting and Audit - The company has not undergone an audit for the third quarter report[31] - The report was issued by the board of directors on October 29, 2021[32]

Financial Performance - The company's operating revenue for the first half of 2021 was approximately ¥623.61 million, representing a 26.51% increase compared to ¥492.92 million in the same period last year[24]. - The net profit attributable to shareholders of the listed company reached approximately ¥19.00 million, a significant turnaround from a loss of ¥37.05 million in the previous year, marking a 151.29% improvement[24]. - The basic earnings per share increased to ¥0.18, compared to a loss of ¥0.35 per share in the previous year, reflecting a 151.43% improvement[24]. - The company achieved a revenue of 623.61 million yuan, representing a year-on-year growth of 26.51%[39]. - The net profit attributable to shareholders reached 19.00 million yuan, marking a significant increase of 151.29% compared to the previous year[39]. - The total operating revenue for the first half of 2021 reached CNY 623,607,764.69, an increase of 26.5% compared to CNY 492,919,460.37 in the first half of 2020[184]. - The net profit for the first half of 2021 was CNY 67,555,080.43, a significant increase from CNY 21,881,079.93 in the first half of 2020, representing a growth of 208.5%[188]. Cash Flow and Assets - The net cash flow from operating activities was approximately ¥8.60 million, a decrease of 95.32% compared to ¥183.64 million in the same period last year[24]. - The company's operating cash flow net amount decreased by 95.32% to ¥8.60 million, primarily due to increased cash outflow from operating activities[55]. - Cash and cash equivalents at the end of the reporting period were ¥385.43 million, accounting for 11.87% of total assets, down from 12.12% the previous year[59]. - The cash flow from financing activities showed a net inflow of 104,197,506.47 CNY, compared to a net outflow of -25,375,430.85 CNY in the first half of 2020[195]. - The total cash inflow from operating activities was 253,436,604.83 CNY, slightly up from 237,133,002.07 CNY in the previous year[194]. - The total assets at the end of the reporting period amounted to 1,711.00 million RMB, compared to 1,664.16 million RMB at the end of the previous period, indicating a growth of approximately 2.82%[200]. Investments and R&D - Research and development expenses amounted to 25.71 million yuan, accounting for 4.12% of the total revenue, maintaining a high investment level[39]. - Research and development investment increased by 52.80% to ¥25.71 million from ¥16.82 million, driven by accelerated project progress[55]. - The company plans to increase R&D investment to accelerate the development and registration of new products[95]. - The company is focused on integrating the entire industry chain from intermediates to raw materials and finished formulations, enhancing its market position[48]. Market and Competitive Position - The company has established long-term and stable partnerships with leading enterprises in the steroid drug industry, enhancing its competitive position[45]. - The company is transitioning from a single steroid raw material supplier to a comprehensive biotechnology enterprise[36]. - China's pharmaceutical market is projected to continue growing, driven by increasing health awareness and an aging population[40]. - The company is focused on becoming a full-chain biotechnology enterprise, integrating intermediates, active pharmaceutical ingredients, and formulations[95]. Environmental Compliance - The company is classified as a key pollutant discharge unit by environmental protection authorities, indicating a significant focus on environmental compliance[117]. - The company has signed a wastewater treatment service agreement with a local water utility, ensuring compliance with wastewater discharge standards[117]. - The company has implemented measures to monitor and control emissions of various pollutants, including ammonia nitrogen and hydrogen sulfide, ensuring compliance with environmental regulations[117]. - The wastewater treatment system has been upgraded, combining two systems to enhance treatment capacity[119]. Corporate Governance and Shareholder Information - The company has not distributed cash dividends or bonus shares for the half-year period[104]. - The company has established a stock incentive plan to enhance the motivation of its management and key technical personnel[105]. - The largest shareholder, Shandong Runxin Investment Co., Ltd., holds 37.11% of shares, totaling 39,802,720 shares[163]. - The company has maintained compliance with information disclosure regulations to protect the rights of minority shareholders[129]. Risk Management - The company has identified several risks, including national policy and industry risks, and has detailed these in the report[7]. - The company faces risks from industry competition and potential price fluctuations in steroid raw materials[94]. - The company has not engaged in any derivative investments or entrusted loans during the reporting period, maintaining a conservative financial strategy[84][85].

Financial Performance - The company's revenue for Q1 2021 was CNY 272,376,194.52, representing a 22.60% increase compared to CNY 222,171,115.42 in the same period last year[8] - The net profit attributable to shareholders was a loss of CNY 5,371,348.90, an improvement of 77.84% from a loss of CNY 24,243,112.96 in the previous year[8] - The basic earnings per share were CNY -0.05, improving by 77.27% from CNY -0.22 in the same period last year[8] - The net profit attributable to shareholders was -5.37 million yuan, an increase of 77.84% year-on-year[26] - The net loss for Q1 2021 was CNY 4,955,375.78, a significant improvement from a net loss of CNY 29,031,607.96 in Q1 2020[51] - The company reported a total comprehensive income of CNY 17,798,306.66 for Q1 2021, compared to CNY 5,255,268.42 in Q1 2020, marking an increase of 237.5%[55] Cash Flow - The net cash flow from operating activities was negative at CNY -57,991,155.87, a decline of 843.09% compared to a positive cash flow of CNY 7,804,016.99 in the same period last year[8] - Cash received from operating activities decreased by 843.09%, resulting in a net cash flow of -57.99 million yuan[25] - The total cash flow from operating activities was negative CNY 57,991,155.87, a decline from a positive cash flow of CNY 7,804,016.99 in the same period last year[58] - The net cash flow from operating activities was ¥55,397,320.47, a decrease of 18% compared to ¥67,688,413.19 in the previous period[60] - Total cash inflow from operating activities amounted to ¥151,868,773.20, up 50% from ¥101,222,822.50 in the prior period[60] Assets and Liabilities - The total assets at the end of the reporting period were CNY 3,011,234,104.57, an increase of 5.98% from CNY 2,841,295,244.66 at the end of the previous year[8] - The total current asset of RMB 1.22 billion, up from RMB 1.14 billion, indicating an increase of about 6.9%[41] - The company's total liabilities reached CNY 1,326,112,564.91, compared to CNY 1,149,916,239.64 in the previous year, marking an increase of 15.4%[45] - The company's total liabilities increased to RMB 1.06 billion from RMB 944.00 million, reflecting an increase of about 12.5%[42] Shareholder Information - The company had a total of 12,222 preferred shareholders at the end of the reporting period[12] - The top ten shareholders held a significant portion of the company's shares, with the largest shareholder holding 39,802,720 shares, representing 37.11% of the total[12] - The total equity attributable to shareholders was CNY 1,637,637,435.80, slightly down from CNY 1,643,008,784.70, a decrease of 0.3%[45] Research and Development - R&D expenses increased by 52.60% to ¥11,286,267.83 as a result of accelerated project development[22] - Research and development expenses for Q1 2021 were CNY 11,286,267.83, an increase of 52.5% from CNY 7,395,918.08 in Q1 2020[51] Government Subsidies - The company received government subsidies amounting to CNY 2,811,471.50 during the reporting period[9] - Other income surged by 129.36% to ¥2,811,471.50 due to increased government subsidies related to operating activities[22] Investment Activities - The company invested 112.10 million yuan in fixed assets and intangible assets, a 94.96% increase compared to the previous year[25] - The company raised CNY 130,000,000.00 through financing activities, an increase from CNY 105,000,000.00 in the previous year[59] Operational Efficiency - The company plans to continue expanding its market presence and investing in R&D for new product development[18] - The company has achieved a production efficiency of 56.28% in its raw material drug project as of May 1, 2022[32] Market and Project Updates - The company is advancing the registration and certification of multiple drugs in the US, domestic, and EU markets, with no significant changes in project feasibility[32] - The company is facing increased external uncertainties and trade protectionism, which may impact project timelines and expected returns[32]

Financial Performance - The company's net profit attributable to shareholders was -179,807,242.83 RMB, a decrease of 425.09% compared to the previous year[6]. - The company's revenue for 2020 was ¥913,187,604.30, a decrease of 5.45% compared to ¥965,800,380.65 in 2019[27]. - The net profit attributable to shareholders was -¥179,807,242.83, representing a decline of 425.09% from a profit of ¥55,309,472.92 in 2019[27]. - The company's basic earnings per share for 2020 was -¥1.68, a decrease of 423.08% from ¥0.52 in 2019[27]. - The weighted average return on equity was -10.31% in 2020, a decline of 13.35% compared to 3.04% in 2019[27]. - The company reported a total of ¥890,079,289.25 in revenue after deducting non-main business income for 2020[28]. - The company reported a total revenue of 327,621,730 for the period, with a net loss of 32,917,769[118]. Cash Flow and Investments - The net cash flow from operating activities increased significantly by 341.89% to ¥254,600,648.67 from ¥57,616,516.66 in 2019[27]. - The company experienced a significant increase in cash flow from operating activities in Q2 2020, reaching ¥175,833,629.63[30]. - The net cash flow from investing activities decreased by 321.91% to -¥29,228,833.40, mainly due to increased project construction payments[85]. - The net cash flow from financing activities decreased by 1,667.27% to -¥140,732,755.48, as loan repayments exceeded new loans during the period[86]. - The company reported a significant increase in finished drug sales, which rose by 277.34% to ¥93,788,143.41[69]. - The company has achieved a cumulative investment progress of 66.24% in its fundraising projects[104]. Strategic Focus and Market Position - The company is focusing on becoming a biotechnology enterprise integrating "pharmaceutical intermediates, active pharmaceutical ingredients, and finished formulations" as part of its long-term strategy[6]. - The company plans to increase investment in high-end specialty raw materials and expand its overseas market presence, particularly through its subsidiary Lisapharma[12]. - The company has established a strategic layout in the respiratory high-end specialty raw materials and formulation products, enhancing its market competitiveness[41]. - The global steroid hormone drug market has been growing at over 10% annually, with a market size exceeding $150 billion in 2020, indicating strong demand for steroid intermediates and raw materials[42]. - The company has successfully entered the formulation field through the acquisition of Lisapharma, establishing a full industry chain from intermediates to raw materials and formulations[44]. - The company aims to upgrade its industry strategy, focusing on high-end specialty raw materials and finished formulations[128]. Operational Challenges and Risks - The company faces industry risks due to increased competition and potential fluctuations in raw material and labor costs[10]. - The ongoing global pandemic may impact the company's business revenue and operational performance, particularly affecting Lisapharma[13]. - The company is actively adjusting its operational strategies to mitigate the adverse effects of the pandemic on its business[13]. - The company has maintained a strong market position in the steroid drug raw material sector despite increased competition and a significant sales decline in Q2 2020[58]. Environmental and Social Responsibility - The company is committed to environmental protection and will continue to improve production processes to reduce waste emissions[15]. - The company has maintained a high standard in environmental management and aims for zero accidents in production safety[133]. - The company actively engages in environmental protection, implementing effective waste management and promoting clean production practices[189]. - During the reporting period, the company donated a total of 250,000 to various charitable organizations and provided over 700,000 in pandemic prevention materials[190]. Governance and Compliance - The company has established a governance structure to enhance the responsibility and mission of senior management and core technical personnel[158]. - The company has fulfilled its commitments regarding the accuracy and completeness of information disclosure related to its stock incentive plan[149]. - The company has maintained a continuous audit relationship with Tianjian Accounting Firm for 9 years, with the current auditors having served for 1 year and 3 years respectively[153]. - There were no major lawsuits or arbitration matters during the reporting period[155]. Research and Development - The company focuses on the production of steroid drug raw materials using genetic engineering and microbial transformation technologies, positioning itself as a key supplier in China[36]. - The company has made significant progress in the research and development of respiratory high-end specialty raw materials, completing domestic registration for several products[59]. - The number of R&D personnel increased to 172, representing 15.49% of the workforce, reflecting a commitment to enhancing R&D capabilities[83]. - R&D investment focused on high-end specialty raw materials, with ongoing projects like Fluticasone propionate[80]. Shareholder Relations and Returns - The company will not distribute cash dividends or issue bonus shares for the current fiscal year[16]. - The cash dividend total for 2020 was 0.00 yuan, representing 0.00% of the total profit distribution[138]. - The company emphasizes shareholder returns while actively fulfilling responsibilities to employees, customers, and society, aiming for sustainable development[184]. - The company has committed to ensuring that the increase in cash dividend amount will at least match the growth rate of net profit if the net profit continues to grow steadily[148].

Financial Performance - Operating revenue for the reporting period was CNY 232,089,006.03, an increase of 12.12% year-on-year[9] - Net profit attributable to shareholders was a loss of CNY 12,075,333.32, a decrease of 161.01% compared to the same period last year[9] - Basic earnings per share were -CNY 0.1129, a decrease of 160.99% compared to the same period last year[9] - The company expects a full-year loss of CNY 40 million due to the impact of the pandemic on its subsidiary Lisapharma in Italy[26] - The net profit for Q3 2020 was a loss of CNY 13,548,149.68, compared to a profit of CNY 19,292,580.06 in the same period last year[45] - The company's operating revenue for the current period is $116.21 million, a decrease of 36.8% compared to $183.70 million in the previous period[48] - Operating profit for the current period is $4.66 million, down 87.5% from $37.17 million in the previous period[48] - Net profit for the current period is $3.21 million, a decline of 90.1% compared to $32.20 million in the previous period[49] - The total comprehensive income for the current period is -$59.28 million, compared to $82.43 million in the previous period[54] - Basic earnings per share for the current period is -$0.4595, compared to $0.7779 in the previous period[54] Cash Flow - Net cash flow from operating activities was CNY 71,829,988.82, an increase of 41.41% year-on-year[9] - The company reported a significant increase in cash flow from operating activities, with a year-to-date increase of 216.46%[9] - The net cash flow from operating activities increased by 216.46% to CNY 255,467,635.44, driven by enhanced collection efforts on accounts receivable[23] - The cash flow from operating activities was not detailed in the provided documents, indicating a need for further analysis on liquidity[46] - The company's total cash inflow from operating activities is ¥698,176,828.78, compared to ¥564,446,033.28 in the previous period, reflecting a positive trend[59] - The net cash flow from operating activities for the period was ¥156,542,251.09, a decrease of 3.9% compared to ¥162,837,035.03 in the previous period[61] Assets and Liabilities - Total assets at the end of the reporting period were CNY 2,865,231,270.92, a decrease of 4.08% compared to the end of the previous year[9] - The company's total assets amounted to CNY 2,724,791,030.04, slightly up from CNY 2,711,411,663.43 in the previous period[41] - Total liabilities decreased to CNY 763,556,434.79 from CNY 765,851,235.65[41] - The total equity of the company increased to CNY 1,961,234,595.25 from CNY 1,945,560,427.78[41] - Total current assets amounted to CNY 793,301,709.00, with cash and cash equivalents at CNY 61,407,367.72 and accounts receivable at CNY 118,813,861.65[71] - Total non-current assets reached CNY 1,918,109,954.43, including long-term receivables of CNY 595,779,233.74 and long-term equity investments of CNY 695,535,959.75[71] - Total liabilities were CNY 765,851,235.65, indicating a manageable debt level relative to assets[72] - Total equity reached CNY 1,945,560,427.78, with retained earnings of CNY 643,825,946.90[73] Shareholder Information - The total number of shareholders at the end of the reporting period was 13,487[13] - The largest shareholder, Shandong Runxin Investment Co., Ltd., held 36.93% of the shares, totaling 39,802,720 shares[13] Expenses and Costs - Sales expenses increased by 108.39% to CNY 12,225,192.85, mainly due to the acquisition of Italian Lisapharma, which expanded the scope of consolidation[21] - Total operating costs increased to CNY 248,450,361.33 from CNY 187,633,553.92, with operating costs specifically rising from CNY 142,043,637.39 to CNY 196,313,382.86[44] - The company reported a decrease in research and development expenses from CNY 11,711,583.82 to CNY 8,231,424.38[44] - Research and development expenses decreased to $25.05 million from $30.95 million, a reduction of 19.1%[52] Government Subsidies - The company received government subsidies amounting to CNY 13,293,017.47 related to its daily operations[10] - Other income surged by 305.17% to CNY 13,293,017.47, attributed to increased government subsidies related to daily operations[21] Financial Commitments - The company has no significant commitments or overdue promises from shareholders or related parties during the reporting period[25] - There were no instances of non-compliance regarding external guarantees or non-operating fund occupation by controlling shareholders during the reporting period[29][30] Future Outlook - The company expects an annual loss due to the renovation project for the new streptomycin, with an estimated scrapped equipment value of approximately CNY 15 million and idle equipment value of about CNY 13 million, pending final audit confirmation[27] - The company is implementing new revenue and leasing standards starting in 2020, which may impact future financial reporting[74] - The company continues to focus on expanding its market presence and enhancing product development strategies[75]

Financial Performance - The company's operating revenue for the first half of 2020 was ¥492,919,460.37, a decrease of 14.98% compared to ¥579,796,218.51 in the same period last year[18]. - The net profit attributable to shareholders of the listed company was a loss of ¥37,050,450.33, representing a decline of 158.40% from a profit of ¥63,437,395.63 in the previous year[18]. - The basic earnings per share for the first half of 2020 was -¥0.35, down 159.32% from ¥0.59 in the same period last year[18]. - Revenue for the reporting period was ¥492,919,460.37, a decrease of 14.98% compared to the same period last year due to reduced delivery volumes and price fluctuations caused by the COVID-19 pandemic[50]. - The net profit for the first half of 2020 was a loss of approximately ¥45.74 million, compared to a profit of ¥63.14 million in the same period of 2019[188]. - The total comprehensive income for the first half of 2020 was a loss of approximately ¥45.74 million, compared to a profit of ¥63.14 million in the same period of 2019[188]. Cash Flow and Assets - The net cash flow from operating activities increased significantly to ¥183,637,646.62, up 513.59% from ¥29,928,520.54 in the same period last year[18]. - Cash and cash equivalents increased by 164.45% to ¥14,006,000.23, reflecting significant growth in operating cash flow[51]. - The total cash and cash equivalents at the end of the period increased to CNY 173,525,543.37 from CNY 57,806,550.10, marking a growth of approximately 200%[196]. - The total assets at the end of the reporting period were ¥2,865,830,573.08, a decrease of 4.06% from ¥2,987,259,062.48 at the end of the previous year[18]. - The company's cash and cash equivalents as of June 30, 2020, amount to ¥201,067,779.54, an increase from ¥183,606,732.94 at the end of 2019[176]. Expenses and Liabilities - Operating costs were ¥436,440,267.87, a slight decrease of 1.19% year-on-year[50]. - Management expenses rose by 118.19% to ¥68,845,000.81, attributed to increased consolidation scope and depreciation from completed projects not yet in production[50]. - Financial expenses increased by 26.79% to ¥18,342,711.55, mainly due to higher bank loan interest expenses[50]. - Total liabilities decreased from CNY 1,100,498,882.82 to CNY 1,028,055,679.98, a decline of about 6.6%[179]. - Current liabilities decreased from CNY 943,052,609.30 to CNY 877,287,972.63, a reduction of approximately 7.0%[178]. Investments and R&D - The company has continuously invested in R&D, enhancing its production processes and developing a range of steroid drug raw materials[38]. - R&D investment decreased by 12.57% to ¥16,823,568.51 compared to the previous year[51]. - The company plans to enhance R&D investment and talent acquisition to optimize new product layouts[99]. - The company has completed the process development and pilot testing for a new steroid intermediate during the reporting period[43]. Market Position and Products - The company is a key supplier of steroid drug raw materials, focusing on research, production, and sales of steroid drugs[25]. - The global steroid hormone drug market has been growing at over 10% annually since the 1990s, indicating a stable demand for steroid intermediates and raw materials[31]. - The company's core business, intermediates, accounted for 77.36% of total revenue during the reporting period[43]. - The company has expanded its product offerings to include high-end respiratory specialty raw materials and various formulations, enhancing its market position[30]. Risk Management - The company has identified several risks including industry risk and environmental risk, which are detailed in the report[5]. - The company emphasizes the importance of understanding the differences between future plans and actual commitments, urging investors to be aware of investment risks[5]. - The company faces industry risks due to increased competition, which may affect pricing and bargaining power[97]. - Environmental risks are heightened due to stricter regulations, impacting operational costs and performance[100]. Environmental Compliance - The company is classified as a key pollutant discharge unit by environmental protection authorities[136]. - The company has implemented advanced wastewater treatment processes, including multi-effect evaporation and Fenton oxidation, to ensure compliance with environmental standards[139]. - Emission standards for various pollutants were met, with specific values such as ammonia at 1.05 mg/L and total sulfur compounds at 3.15 mg/Nm³[140]. - The company has established high-standard storage facilities for hazardous waste, ensuring safe and environmentally friendly handling[141]. Shareholder Information - The annual shareholders' meeting had a participation rate of 44.30%[105]. - The largest shareholder, Shandong Runxin Investment Co., Ltd., holds 36.93% of shares, totaling 39,802,720 shares, with 19,676,000 shares pledged[158]. - Shareholder Mi Chaojie holds 22.68% of shares, totaling 24,448,000 shares, with 18,336,000 shares under selling restrictions[158]. Corporate Governance - The company plans not to distribute cash dividends or issue bonus shares[6]. - The company has fulfilled all commitments made by actual controllers, shareholders, and related parties during the reporting period[107]. - The company has not undergone any bankruptcy reorganization during the reporting period[110]. - There were no significant litigation or arbitration matters during the reporting period[111].

Financial Performance - The company's operating revenue for 2019 was approximately ¥965.8 million, a decrease of 8.22% compared to ¥1,052.3 million in 2018[28]. - The net profit attributable to shareholders for 2019 was approximately ¥55.3 million, down 56.13% from ¥126.1 million in the previous year[28]. - Basic earnings per share for 2019 were ¥0.52, a decline of 55.93% from ¥1.18 in 2018[28]. - The company reported a total revenue of 11,575,928.88 in the current period, compared to 23,484,513.50 in the previous period, indicating a significant decrease[35]. - The company achieved a net profit of -15.55 million yuan during the reporting period[49]. - The company reported a total revenue of 199.12 million, with a net loss of 19.587 million for the reporting period[97]. - The company's net profit attributable to shareholders for the year was CNY 55,309,472.92, with a distributable profit of CNY 535,772,779.26 as of December 31, 2019[145]. Investments and Acquisitions - The company acquired Lisapharma to enhance its international market presence and expand its product line in high-end specialty raw materials[15]. - The company invested a total of 55.79 million yuan in R&D, accounting for 5.78% of total revenue and 86.21% of profit, with a team of 158 R&D personnel[52]. - The company acquired 83.08% of Lisapharma, with a total investment of 158.45 million yuan, enhancing its presence in the formulation sector[49]. - The company has invested 11,460.00 million to acquire 100% equity of Runxin Thermal Power, fully utilizing the fundraising for this purpose[110]. - The company has made strategic investments in Lisapharma to enhance its production capabilities and expand its overseas market presence[118]. Research and Development - The company is focusing on enhancing its R&D capabilities and has made progress in developing high-end specialty raw materials, including Fluticasone propionate[15]. - The company plans to accelerate the development of high-end specialty raw materials, focusing on respiratory drugs like Fluticasone propionate[81]. - R&D investment increased significantly due to the addition of three new high-end raw material drug projects and the expansion of the R&D team[82]. - The company has a total of 17 patents, with 4 new patents granted during the reporting period[52]. - The company will enhance its R&D capabilities by increasing investment and recruiting top talent, especially after acquiring Lisapharma, which complements its domestic R&D platform[133]. Market and Industry Position - The company is a key supplier of steroid drug raw materials in China, utilizing gene engineering and microbial transformation technologies[38]. - The global steroid hormone drug market has been growing at over 10% annually since the 1990s, ensuring stable demand for steroid intermediates and raw materials[44]. - The company has become a leading domestic supplier of steroid drug raw materials by leveraging advanced gene engineering and fermentation technologies[45]. - The company has identified market opportunities in high-end respiratory specialty raw materials, indicating a strategic focus on this segment[14]. - The company has increased its market share in steroid intermediates due to competitive pricing strategies implemented over the past few years[133]. Operational Efficiency and Challenges - The company is committed to improving its operational efficiency and sustainable development capabilities in response to market challenges[16]. - The company acknowledges risks related to the COVID-19 pandemic, which may impact revenue and operational performance in 2020[6]. - The company faces industry risks due to increased competition and potential fluctuations in raw material prices, which could affect profitability[7]. - The company emphasizes the importance of upgrading its industrial capabilities to maintain competitive advantages amid market changes[9]. - The company is focusing on enhancing its management level and optimizing resource allocation to improve operational efficiency and profitability[134]. Financial Health and Cash Flow - The net cash flow from operating activities improved significantly, reaching approximately ¥57.6 million, compared to a negative cash flow of ¥335.3 million in 2018, marking a 117.18% increase[28]. - Operating cash inflow totaled ¥745,708,794.53 in 2019, a 5.12% increase year-over-year, while cash outflow decreased by 34.13%[84]. - The net cash flow from investment activities increased by 103.46% to ¥13,171,668.65, attributed to decreased short-term investment purchases and the acquisition of Lisapharma[84]. - The company has a total of 102.563 million raised from public offerings, with 79.739 million already utilized, representing 66.24% of the total[103]. - The company has a net balance of RMB 6,510.99 million in the special account for raised funds after deducting bank fees[111]. Environmental and Social Responsibility - The company is committed to environmental protection and has implemented measures to reduce pollution and manage waste effectively[139]. - The company has maintained a strong focus on corporate social responsibility, emphasizing shareholder returns and employee welfare[189]. - The company is classified as a key pollutant discharge unit, with specific pollutants monitored and treated according to environmental standards[197]. - Wastewater is treated through advanced processes including multi-effect evaporation and Fenton oxidation, ensuring compliance with discharge standards[198]. - The company employs various methods for exhaust gas treatment, including alkaline spraying and catalytic oxidation, to ensure emissions meet regulatory requirements[199]. Shareholder Commitments and Governance - The company plans to distribute a cash dividend of 0.52 yuan per 10 shares (including tax) based on a total of 107,783,667 shares[12]. - The company has committed to repurchase all newly issued shares from its initial public offering, ensuring compensation for investors in case of losses due to misleading statements in the prospectus[153]. - The company promises to distribute cash dividends of no less than 10% of the distributable profits each year, with an increase in cash dividends aligned with net profit growth if profits remain stable[153]. - The company has undertaken to maintain a stable growth in net profit, with cash dividend increases at least matching the growth rate of net profits[153]. - The company has established a governance structure with a shareholders' meeting, board of directors, and supervisory board, enhancing operational standards and protecting shareholder rights[193].

Financial Performance - Total revenue for Q1 2020 was ¥222,171,115.42, a decrease of 22.68% compared to ¥287,321,415.48 in the same period last year[8] - Net profit attributable to shareholders was -¥24,243,112.96, representing a decline of 175.65% from ¥32,045,197.48 year-on-year[8] - Basic earnings per share decreased to -¥0.2249, down 174.87% from ¥0.3004 in the same period last year[8] - The company's operating revenue for Q1 2020 was RMB 222,171,115.42, a decrease of 22.68% compared to RMB 287,321,415.48 in Q1 2019[25] - The net profit attributable to shareholders was -¥2,424.31 million, a decrease of 175.65% year-on-year, largely due to the impact of COVID-19 on market demand and production resumption[27] - The company reported a net profit for Q1 2020 of a loss of CNY 29,553,800.45, compared to a profit of CNY 31,909,160.06 in Q1 2019, representing a significant decline[50] - The company's operating profit for Q1 2020 was a loss of CNY 28,274,348.25, compared to a profit of CNY 37,751,064.54 in the previous year[49] Cash Flow - The net cash flow from operating activities improved to ¥7,804,016.99, a significant increase of 110.78% compared to -¥72,372,553.44 in the previous year[8] - The net cash flow from operating activities increased by 110.78% year-on-year, reaching ¥7,804,016.99, primarily due to reduced raw material procurement and a shift to bank acceptance bills[27] - The net cash flow from investing activities decreased by 346.51% year-on-year, amounting to -¥89,946,490.16, mainly due to increased investments in bank wealth management products[27] - The net cash flow from financing activities grew by 110.55% year-on-year to ¥22,487,003.46, driven by increased bank loans to supplement working capital[27] - Cash inflow from operating activities totaled CNY 163,102,464.55, down from CNY 184,163,186.63 year-over-year, representing a decrease of approximately 11%[56] - The net cash flow from investing activities was negative at CNY -89,946,490.16, contrasting with a positive CNY 36,488,030.24 in the same period last year[58] - The net cash flow from financing activities was CNY 22,487,003.46, compared to CNY 10,680,332.54 in the previous year, reflecting a growth of about 110%[58] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,911,972,514.39, a decrease of 2.52% from ¥2,987,259,062.48 at the end of the previous year[8] - Total liabilities decreased by 4.19% to RMB 1,054,376,001.75 from RMB 1,100,498,882.82[24] - Total current assets decreased from CNY 1,506,704,686.33 to CNY 1,420,501,904.10, a decline of approximately 5.73%[40] - Total current liabilities were CNY 943,052,609.30, while total liabilities stood at CNY 1,100,498,882.82[64] - Total equity decreased from CNY 1,886,760,179.66 to CNY 1,857,596,512.64, a decline of about 1.54%[43] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 14,317[12] - The largest shareholder, Shandong Runxin Investment Co., Ltd., held 36.93% of the shares, totaling 39,802,720 shares[12] Operational Changes and Future Plans - The company plans to continue expanding its market presence and product offerings in response to the challenges posed by the pandemic[19] - The company has decided to terminate the projects for producing 120 tons of 4-androstenedione and 180 tons of hydroxyprogesterone due to significant changes in market prices and demand[34] - The company has prioritized the production line construction and qualification application for key products while extending the construction period for non-key products[34] - The company plans to extend the project construction period by two years, with completion now expected by May 1, 2022[34] Regulatory and Compliance - The company has not reported any violations regarding external guarantees during the reporting period[36] - There are no non-operating fund occupations by controlling shareholders or related parties during the reporting period[37] - The company has implemented new revenue recognition and leasing standards effective January 1, 2020, impacting financial reporting[71] - The Q1 2020 report was not audited, indicating preliminary financial results[71]

Financial Performance - Operating revenue for the reporting period was ¥206,998,521.26, a decrease of 27.75% year-on-year[9] - Net profit attributable to shareholders was ¥19,791,862.76, down 33.25% compared to the same period last year[9] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥18,181,319.45, a decrease of 17.35% year-on-year[9] - Basic earnings per share for the reporting period was ¥0.1851, down 32.59% compared to the same period last year[9] - The weighted average return on net assets was 1.07%, a decrease of 0.52% compared to the previous year[9] - The company reported a decrease in net profit guidance for the upcoming quarter, reflecting ongoing market challenges[9] - Total operating revenue for Q3 2019 was CNY 206,998,521.26, a decrease of 27.8% compared to CNY 286,508,705.48 in the same period last year[38] - Net profit for Q3 2019 was CNY 19,292,580.06, representing a decline of 35.6% from CNY 29,956,040.16 in Q3 2018[39] - The company reported a total profit of ¥96,763,935, down from ¥121,882,847, reflecting a decrease of about 20.6%[47] - The company’s total comprehensive income for the current period is ¥82,433,334, compared to ¥100,408,496 in the previous period, indicating a decrease of about 17.9%[49] Cash Flow - The net cash flow from operating activities for the year-to-date was ¥80,725,716.51, an increase of 129.60%[9] - The net cash flow from operating activities improved by 128.42%, reaching ¥80,725,716.51, due to reduced raw material purchases and improved payment methods[20] - Cash flow from operating activities generated a net amount of ¥80.73 million, a significant improvement from a net outflow of ¥284.05 million in the previous period[54] - Net cash flow from operating activities was CNY 162,837,035.03, compared to a negative CNY 214,971,814.47 in the same period last year[56] Assets and Liabilities - Total assets at the end of the reporting period reached ¥2,956,164,093.12, an increase of 5.39% compared to the end of the previous year[9] - Total liabilities reached CNY 1,037,690,799.67, up from CNY 844,347,122.68, indicating an increase of approximately 23%[30] - The company's equity attributable to shareholders decreased to CNY 1,865,677,819.54 from CNY 1,907,145,232.71, a decline of about 2.2%[31] - Total assets increased to CNY 2,790,749,742.23, compared to CNY 2,542,968,929.67 at the end of the previous year[36] - Total liabilities rose to CNY 842,659,454.54, up from CNY 672,039,386.23 year-on-year[35] - Total liabilities amounted to CNY 844,347,122.68, with non-current liabilities totaling CNY 98,499,305.89[63] Expenses - Sales expenses decreased by 32.65% to ¥5,866,523.51, due to optimized personnel structure and reduced exhibition costs[20] - Financial expenses rose by 60.78% to ¥24,685,032.95, driven by increased bank loans and financing costs[20] - The company reported a decrease in management expenses to CNY 20,601,473.41 from CNY 12,890,868.64, reflecting a 59.9% increase year-on-year[38] - The company’s management expenses increased to ¥52,154,573 from ¥43,031,227, representing an increase of approximately 21.8%[47] Investments - The investment cash flow net amount decreased by 49.33% to -¥113,018,451.77, mainly due to an increase in the net amount recovered from short-term financial products[20] - The company reported a significant increase in cash received from other investment activities, totaling CNY 623,177,017.88 compared to CNY 228,000,000.00 last year[56] Shareholder Information - The top shareholder, Shandong Runxin Investment Co., Ltd., holds 36.87% of the shares, with a total of 39,802,720 shares pledged[13] - The company did not execute any cash dividend policy during the reporting period[23] - There were no non-operating fund occupations by controlling shareholders or related parties during the reporting period[24] Other Financial Metrics - Other income surged by 280.09% to ¥3,280,882.50, primarily from increased government subsidies related to daily operations[20] - Research and development expenses for Q3 2019 were CNY 11,711,583.82, an increase of 84.5% compared to CNY 6,355,781.34 in the same period last year[38] - Research and development expenses increased to ¥9,007,746 from ¥5,681,461, marking a rise of about 58.5%[43]

Financial Performance - The company reported a significant increase in revenue, with a year-on-year growth of 20% in the first half of 2019[1]. - Total revenue for the reporting period was ¥579,796,218.51, an increase of 3.42% compared to the same period last year[25]. - Net profit attributable to shareholders decreased by 9.14% to ¥63,437,395.63 from ¥69,955,208.74 in the previous year[25]. - Net profit after deducting non-recurring gains and losses was ¥53,428,121.29, down 12.30% from ¥61,057,206.02[25]. - Basic and diluted earnings per share decreased by 9.23% to ¥0.59 from ¥0.65[26]. - The company reported a significant increase in net cash flow from operating activities, up 115.64% compared to the previous year[55]. - The net cash flow from operating activities for the first half of 2019 was ¥29,928,520.54, a significant improvement compared to a net loss of ¥191,384,423.15 in the same period of 2018[194]. - Total operating revenue for the first half of 2019 was CNY 579,796,218.51, an increase of 3.9% compared to CNY 560,631,501.48 in the same period of 2018[185]. - Net profit for the first half of 2019 was CNY 63,140,753.96, a decrease of 10.4% from CNY 70,452,455.83 in the first half of 2018[186]. Assets and Liabilities - The total assets of the company reached RMB 1.5 billion, reflecting a 15% increase compared to the same period last year[1]. - Total assets at the end of the reporting period were ¥2,787,741,914.86, a slight decrease of 0.62% from the previous year[26]. - Total liabilities increased to CNY 890,173,422.07 from CNY 844,347,122.68, representing an increase of approximately 5.4%[178]. - The company's equity attributable to shareholders decreased to CNY 1,844,273,736.18 from CNY 1,907,145,232.71, a decline of approximately 3.3%[178]. Investment and R&D - The company is committed to enhancing its research and development capabilities to drive innovation and product upgrades in the steroid drug market[6]. - The company invested RMB 19.24 million in R&D, a decrease of 32.55% compared to the previous year, due to reduced funding for certain projects[55]. - The company has developed a series of products including Dehydroepiandrosterone (AD), Androstenedione (ADD), and 9-Hydroxy-Dehydroepiandrosterone (9OH-AD) through independent research and development[45]. - The company is focused on talent acquisition to build a strong and efficient professional team, enhancing its development capabilities[52]. Market Strategy and Risks - The company plans to expand its market presence by increasing the number of clients and optimizing customer structure to reduce reliance on major clients[9]. - The company is facing risks related to high customer concentration, which may impact profitability due to increased bargaining power of downstream enterprises[9]. - The company anticipates potential fluctuations in net profit due to competitive pressures and market dynamics in the steroid drug sector[94]. - The company is actively addressing environmental and safety regulatory risks by increasing investments in sustainable practices and risk management[10]. Environmental Compliance - The company is classified as a key pollutant discharge unit by environmental protection authorities[140]. - The company has implemented advanced wastewater treatment processes, including distillation and Fenton oxidation, to ensure compliance with discharge standards[144]. - The company has established high-standard storage facilities for general and hazardous waste, ensuring stable operation of pollution control measures[146]. - There were no environmental pollution incidents or violations of environmental regulations during the reporting period[146]. Corporate Governance - The company has established a sound corporate governance structure to manage the risks associated with rapid expansion and ensure effective internal controls[8]. - The company’s financial report has been verified for accuracy and completeness by its board of directors and senior management[4]. - The company has implemented a stock incentive plan to enhance the responsibility and mission of senior management and core technical personnel[120]. Shareholder Information - The company did not distribute cash dividends or issue bonus shares for the half-year period, nor did it increase capital using reserves[106]. - The participation rate of investors in the first temporary shareholders' meeting was 43.52%, while the annual shareholders' meeting had a participation rate of 43.32%[105]. - The largest shareholder, Shandong Runxin Investment Co., Ltd., holds 36.86% of shares, totaling 39,802,720 shares[159].